Revolution Medicines draws USD 250 million Royalty Pharma Tranche A term loan after FDA approval of RASONQUE

• Revolution Medicines drew USD 250 million under Royalty Pharma’s senior secured term loan facility tied to FDA approval of RASONQUE (daraxonrasib).
• Funding occurred on Oct. 8, 2026 under Tranche A of a USD 750 million facility arranged with Wilmington Trust as administrative agent.
• Draw carried a USD 5 million fee; interest floats at three-month Term SOFR, subject to a 3.50% floor, plus 5.75%.
• Loan is interest-only with principal due Oct. 8, 2032; voluntary prepayment requires repayment of all outstanding Tranche A.
• Company declined Royalty Pharma’s optional Tranche 3 royalty purchase, foregoing up to USD 250 million in proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628171-26-000004), on October 13, 2026, and is solely responsible for the information contained therein.